| ENZON PHARMACEUTICALS, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122956 | METHODS FOR INHIBITING ANGIOGENESIS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN - The present invention relates to methods of inhibiting angiogenesis in mammals. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. The present invention also relates to methods of treating a disease associated with angiogenesis in mammals by administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. | 05-17-2012 |
| 20120076781 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES - One aspect of the invention provides methods for treating cancers which are resistant to treatment with a protein tyrosine kinase inhibitor by co-treatment with the protein tyrosine kinase inhibitor and one or more antisense oligomers that reduce the expression of HER3 and/or HER2 and/or EGFR. Another aspect of the invention provides methods for treating cancers by co-treatment with an inhibitor of HER2 and one or more antisense oligomers that reduce the expression of HER3. | 03-29-2012 |
| 20120004288 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION - The invention relates to oligomer compounds (oligomers), which target beta-catening mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment. | 01-05-2012 |
| 20120004285 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY - The invention relates to pharmaceutical compositions for and methods of treatment with HER3-targeted combination therapy. The invention relates to pharmaceutical compositions comprising an oligomer which targets HER3 (and optionally one or more of HER2 and EGFR) mRNA in a cell, leading to reduced expression of HER3 and optionally HER2 and/or EGFR, and a small molecule protein tyrosine kinase inhibitor of one or more receptor tyrosine kinases, leading to inhibition of signaling and/or internalization of receptor dimers into the cell. The combination therapy is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides methods of treating hyperproliferative disorders with a combination of an oligomer and a protein tyrosine kinase inhibitor. | 01-05-2012 |
| 20110319471 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR - The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment. | 12-29-2011 |
| 20110305770 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker. | 12-15-2011 |
| 20110305769 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 12-15-2011 |
| 20110230420 | RELEASABLE CONJUGATES FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention is directed to nucleic acids delivery systems and methods of modulating an expression of a target gene using the same. In particular, the invention relates to nucleic acids conjugates containing an endosomal release-promoting moiety. The nucleic acids conjugates further contain a nuclear localization signal moiety, and/or a cell targeting moiety. | 09-22-2011 |
| 20110229581 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same. | 09-22-2011 |
| 20110224285 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1A EXPRESSION - Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof. | 09-15-2011 |
| 20110223257 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention relates to releasable fusogenic lipids and nanoparticle compositions containing the same for the delivery of oligonucleotides and methods of modulating gene expression using the same. In particular, this invention relates to releasable fusogenic lipids containing an imine linker and a zwitterionic moiety. | 09-15-2011 |
| 20110195990 | TREATMENT OF RESISTANT OR REFRACTORY CANCERS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN - A method of treating a resistant or refractory cancer in a mammal includes administering an effective amount of a compound of | 08-11-2011 |
| 20110183931 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION - The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( | 07-28-2011 |
| 20110152348 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS - The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers. | 06-23-2011 |
| 20110144185 | RNA ANTAGONISTS TARGETING HSP27 - The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of Hsp27 using said oligomers, including methods of treatment | 06-16-2011 |
| 20110124709 | RNA ANTAGONISTS TARGETING GLI2 - The present invention relates to oligomer compounds (oligomers), which target GLI2 mRNA in a cell, leading to reduced expression of GLI2. Reduction of GLI2 expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer. | 05-26-2011 |
| 20110111044 | NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to nanoparticle compositions for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 05-12-2011 |
| 20110105413 | POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES - The present invention provides polymeric prodrugs including an intracellular releasable disulfide linker for the delivery of oligonucleotides. Methods of making the compounds as well as methods of delivering nucleic acids to tumor cells in a mammal using the same are also provided. | 05-05-2011 |
| 20110086902 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION - The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment. | 04-14-2011 |
| 20110077285 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION - The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using the oligomers, including methods of treatment. | 03-31-2011 |
| 20100279408 | POLYMERIC SHORT INTERFERING RNA CONJUGATES - The present invention provides polymeric siRNA conjugates. Methods for down-regulation of gene expression in vivo and in vitro and for inhibition of the growth of cancer cells using the conjugates are also disclosed. | 11-04-2010 |
| 20100234451 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR - The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment. | 09-16-2010 |
| 20100234444 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY - The invention provides hindered ester-based biodegradable linkers for the delivery of oligonucleotides in vivo, as well as method of making and using the same. | 09-16-2010 |
| 20100233190 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS - The present invention provides single chain antibody-directed polymeric prodrugs containing multifunctional linkers. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 09-16-2010 |
| 20100204261 | MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN FOR TREATMENT OF BREAST, COLORECTAL, PANCREATIC, OVARIAN AND LUNG CANCERS - A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, | 08-12-2010 |
| 20100203066 | POLYMERIC LINKERS CONTAINING PYRIDYL DISULFIDE MOIETIES - The present invention provides polymeric linkers containing pyridyl disulfide moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed. | 08-12-2010 |
| 20100160365 | TREATMENT OF NON-HODGKIN'S LYMPHOMAS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN - The present invention relates to methods of treatment of non-Hodgkin's lymphomas. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof. | 06-24-2010 |
| 20100093839 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1alpha EXPRESSION - Oligonucleotides directed against the hypoxia-inducible factor-1α (HIP-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof. | 04-15-2010 |
| 20100056555 | METHOD OF TREATING RAS ASSOCIATED CANCER - New methods of treating Ras associated cancer, and especially for treating cancer that is resistant or refractory to other treatment methods, including resistant or refractory to treatment with C225 and/or CPT-11, are provided. The new methods employ PEG-conjugated 7-ethyl-10-hydroxycampothecin, alone, or in combination with other art-known anticancer agents or modalities. | 03-04-2010 |
| 20100056543 | POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF - Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons. | 03-04-2010 |
| 20090318538 | POLYMERIC OLIGONUCLEOTIDE PRODRUGS - Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed. | 12-24-2009 |
| 20090286859 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1a EXPRESSION - The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( | 11-19-2009 |
| 20090232833 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS - The present invention provides polymeric delivery systems including hindered ester moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 09-17-2009 |
| 20090221471 | PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES - Vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are hydrolysis resistant in vitro, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed. | 09-03-2009 |
| 20090214472 | Interferon-beta polymer conjugates - Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed. | 08-27-2009 |
| 20090203706 | LYSINE-BASED POLYMERIC LINKERS - The present invention provides polymeric linkers containing branching moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed. | 08-13-2009 |
| 20090202573 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES - The present invention provides polymeric conjugates containing positively charged moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 08-13-2009 |
| 20090156629 | INDENOISOQUINOLINE-RELEASABLE POLYMER CONJUGATES - The present invention provides releasably-linked indenoisoquinoline polymer conjugates. Methods of making the conjugates and methods of treating mammals using the same are also disclosed. | 06-18-2009 |
| 20090074706 | MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN FOR TREATMENT OF BREAST, COLORECTAL, PANCREATIC, OVARIAN AND LUNG CANCERS - A four arm-polyethylene glycol-7-ethyl-10-hydroxycamptothecin conjugate, such as, | 03-19-2009 |
| 20090047271 | STABLE RECOMBINANT ADENOSINE DEAMINASE - A mutein recombinant adenosine deaminase having any oxidizable cysteine residue replaced by a non-oxidizable amino acid residue is disclosed. Stabilized recombinant adenosine deaminase, polymer conjugates and methods of treatment using the same are also disclosed. | 02-19-2009 |
| 20090047270 | ENZYMATIC ANTICANCER THERAPY - What is provided is a method of treating a patient having a tumor comprising administering an effective amount of adenosine deaminase, preferably polyalkylene oxide conjugated, to a patient in need thereof. | 02-19-2009 |
| 20090019954 | CONNECTOR ENABLING MULTIPLE SAMPLING OF SEALED ENVIRONMENT - Connector which provide conduits between a sealed environment and an exterior of the environment includes a housing, a plurality of internal conduits extending from a first side of the housing, each adapted to communicate with a respective sampling device situated in the sealed environment, and a single external conduit extending from a second side of the housing opposite the first side and adapted to communicate with a measurement device exterior of the sealed environment. The housing is constructed to enable each internal conduits to alternatingly align with the external conduit such that each sampling device is able to communicate with the measurement device. By providing a connector which is able to provide a flow passage between multiple sampling devices and a single measurement device, at different times, it is not necessary to enter the sealed environment in order to configure a single sampling device in communication with the measurement device. | 01-22-2009 |
| 20090017004 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID - The present invention provides polymeric delivery systems including an aromatic allyllic acyl group. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 01-15-2009 |
| 20090016985 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY - The present invention provides polymeric delivery systems including a multi-substituted aromatic moiety. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 01-15-2009 |
| 20080305070 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS - Activated polymeric bicine derivatives such as, | 12-11-2008 |
